121 related articles for article (PubMed ID: 38321252)
1. HHLA2 is more significantly associated with poor prognosis in TSCC than PD-L1.
Li Y; Yang Q; Yang X; Ge J; Xu T; Liu H
J Oral Pathol Med; 2024 Feb; 53(2):159-168. PubMed ID: 38321252
[TBL] [Abstract][Full Text] [Related]
2. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
3. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
4. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
[TBL] [Abstract][Full Text] [Related]
5. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
Liao X; Zhang D
Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and prognostic significance of PD-1/PD-L1 axis expression in patients with tongue squamous cell carcinoma.
Huang W; Zhou X; Liao Q; Tang Y; Zuo L; Wang H; Chen X; Chen X; Li J; Zhu S; Deng J; Liu Y; Zhu K; Yu J; Xiong W
J Cell Physiol; 2020 Oct; 235(10):6942-6953. PubMed ID: 32030768
[TBL] [Abstract][Full Text] [Related]
7. Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.
Xia C; Huang W; Chen YL; Fu HB; Tang M; Zhang TL; Li J; Lv GH; Yan YG; Ouyang ZH; Yao N; Wang C; Zou MX
Front Immunol; 2021; 12():797407. PubMed ID: 35145510
[TBL] [Abstract][Full Text] [Related]
8. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.
Wang B; Ran Z; Liu M; Ou Y
Front Immunol; 2019; 10():1573. PubMed ID: 31379814
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Furukawa K; Kawasaki G; Yoshida T; Umeda M
Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
[TBL] [Abstract][Full Text] [Related]
12. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
[TBL] [Abstract][Full Text] [Related]
13. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.
Long L; Zhang L; Yang Y; Zhou Y; Chen H
Immunotherapy; 2022 Apr; 14(6):419-431. PubMed ID: 35187955
[No Abstract] [Full Text] [Related]
14. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
Chen Y; Hu R; Li X; Shi Z; Tian H; Feng J; Yu S
Pathol Res Pract; 2020 Oct; 216(10):153134. PubMed ID: 32853956
[TBL] [Abstract][Full Text] [Related]
15. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
16. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel subtypes based on ssGSEA in immune-related prognostic signature for tongue squamous cell carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Chen X; Cao K
Cancer Med; 2021 Dec; 10(23):8693-8707. PubMed ID: 34668665
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in tongue squamous cell carcinoma.
Akisada N; Nishimoto K; Takao S; Gion Y; Marunaka H; Tachibana T; Makino T; Miki K; Akagi Y; Tsumura M; Toji T; Yoshino T; Nishizaki K; Orita Y; Sato Y
Med Mol Morphol; 2021 Mar; 54(1):52-59. PubMed ID: 32699939
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
